|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GMPS |
Gene summary for GMPS |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GMPS | Gene ID | 8833 |
| Gene name | guanine monophosphate synthase | |
| Gene Alias | GATD7 | |
| Cytomap | 3q25.31 | |
| Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | A0A140VJK6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8833 | GMPS | GSM4909282 | Human | Breast | IDC | 4.61e-11 | 4.14e-01 | -0.0288 |
| 8833 | GMPS | GSM4909285 | Human | Breast | IDC | 4.27e-38 | 7.13e-01 | 0.21 |
| 8833 | GMPS | GSM4909287 | Human | Breast | IDC | 5.48e-06 | 3.17e-01 | 0.2057 |
| 8833 | GMPS | GSM4909293 | Human | Breast | IDC | 7.98e-06 | 2.20e-01 | 0.1581 |
| 8833 | GMPS | GSM4909297 | Human | Breast | IDC | 3.12e-03 | -5.68e-02 | 0.1517 |
| 8833 | GMPS | GSM4909311 | Human | Breast | IDC | 4.94e-08 | -1.49e-01 | 0.1534 |
| 8833 | GMPS | GSM4909319 | Human | Breast | IDC | 2.85e-12 | -1.17e-01 | 0.1563 |
| 8833 | GMPS | GSM4909321 | Human | Breast | IDC | 2.89e-04 | -7.85e-02 | 0.1559 |
| 8833 | GMPS | M2 | Human | Breast | IDC | 1.14e-02 | 2.49e-01 | 0.21 |
| 8833 | GMPS | NCCBC14 | Human | Breast | DCIS | 8.93e-07 | 2.83e-01 | 0.2021 |
| 8833 | GMPS | NCCBC5 | Human | Breast | DCIS | 1.58e-04 | 6.48e-03 | 0.2046 |
| 8833 | GMPS | P1 | Human | Breast | IDC | 2.70e-05 | 1.75e-02 | 0.1527 |
| 8833 | GMPS | P2 | Human | Breast | IDC | 1.01e-13 | 5.56e-01 | 0.21 |
| 8833 | GMPS | DCIS2 | Human | Breast | DCIS | 5.23e-47 | 2.22e-01 | 0.0085 |
| 8833 | GMPS | CCI_2 | Human | Cervix | CC | 6.32e-12 | 1.34e+00 | 0.5249 |
| 8833 | GMPS | CCI_3 | Human | Cervix | CC | 4.94e-08 | 6.61e-01 | 0.516 |
| 8833 | GMPS | Tumor | Human | Cervix | CC | 1.68e-06 | 2.64e-01 | 0.1241 |
| 8833 | GMPS | sample3 | Human | Cervix | CC | 7.86e-10 | 2.82e-01 | 0.1387 |
| 8833 | GMPS | T3 | Human | Cervix | CC | 2.88e-13 | 2.95e-01 | 0.1389 |
| 8833 | GMPS | LZE2T | Human | Esophagus | ESCC | 1.26e-07 | 1.07e+00 | 0.082 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000915214 | Breast | IDC | purine ribonucleotide biosynthetic process | 34/1434 | 169/18723 | 1.63e-07 | 8.92e-06 | 34 |
| GO:004639013 | Breast | IDC | ribose phosphate biosynthetic process | 36/1434 | 190/18723 | 3.40e-07 | 1.73e-05 | 36 |
| GO:000926013 | Breast | IDC | ribonucleotide biosynthetic process | 35/1434 | 182/18723 | 3.40e-07 | 1.73e-05 | 35 |
| GO:000915014 | Breast | IDC | purine ribonucleotide metabolic process | 55/1434 | 368/18723 | 1.30e-06 | 5.72e-05 | 55 |
| GO:001969314 | Breast | IDC | ribose phosphate metabolic process | 58/1434 | 396/18723 | 1.31e-06 | 5.73e-05 | 58 |
| GO:000675313 | Breast | IDC | nucleoside phosphate metabolic process | 68/1434 | 497/18723 | 2.01e-06 | 8.23e-05 | 68 |
| GO:000911713 | Breast | IDC | nucleotide metabolic process | 67/1434 | 489/18723 | 2.28e-06 | 9.05e-05 | 67 |
| GO:000925914 | Breast | IDC | ribonucleotide metabolic process | 56/1434 | 385/18723 | 2.47e-06 | 9.63e-05 | 56 |
| GO:000616413 | Breast | IDC | purine nucleotide biosynthetic process | 34/1434 | 191/18723 | 3.11e-06 | 1.15e-04 | 34 |
| GO:190129313 | Breast | IDC | nucleoside phosphate biosynthetic process | 41/1434 | 256/18723 | 5.15e-06 | 1.73e-04 | 41 |
| GO:000616314 | Breast | IDC | purine nucleotide metabolic process | 56/1434 | 396/18723 | 5.90e-06 | 1.90e-04 | 56 |
| GO:007252213 | Breast | IDC | purine-containing compound biosynthetic process | 34/1434 | 200/18723 | 8.79e-06 | 2.50e-04 | 34 |
| GO:000916513 | Breast | IDC | nucleotide biosynthetic process | 40/1434 | 254/18723 | 1.01e-05 | 2.81e-04 | 40 |
| GO:007252114 | Breast | IDC | purine-containing compound metabolic process | 57/1434 | 416/18723 | 1.28e-05 | 3.31e-04 | 57 |
| GO:000915223 | Breast | DCIS | purine ribonucleotide biosynthetic process | 34/1390 | 169/18723 | 7.77e-08 | 4.47e-06 | 34 |
| GO:004639022 | Breast | DCIS | ribose phosphate biosynthetic process | 36/1390 | 190/18723 | 1.59e-07 | 8.19e-06 | 36 |
| GO:000926022 | Breast | DCIS | ribonucleotide biosynthetic process | 35/1390 | 182/18723 | 1.62e-07 | 8.24e-06 | 35 |
| GO:001969324 | Breast | DCIS | ribose phosphate metabolic process | 58/1390 | 396/18723 | 4.80e-07 | 2.11e-05 | 58 |
| GO:000915024 | Breast | DCIS | purine ribonucleotide metabolic process | 55/1390 | 368/18723 | 4.92e-07 | 2.14e-05 | 55 |
| GO:000925924 | Breast | DCIS | ribonucleotide metabolic process | 56/1390 | 385/18723 | 9.44e-07 | 3.79e-05 | 56 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa012325 | Esophagus | ESCC | Nucleotide metabolism | 59/4205 | 85/8465 | 1.67e-04 | 6.58e-04 | 3.37e-04 | 59 |
| hsa0123212 | Esophagus | ESCC | Nucleotide metabolism | 59/4205 | 85/8465 | 1.67e-04 | 6.58e-04 | 3.37e-04 | 59 |
| hsa012322 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
| hsa009832 | Liver | HCC | Drug metabolism - other enzymes | 54/4020 | 80/8465 | 2.25e-04 | 1.09e-03 | 6.08e-04 | 54 |
| hsa012323 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
| hsa009833 | Liver | HCC | Drug metabolism - other enzymes | 54/4020 | 80/8465 | 2.25e-04 | 1.09e-03 | 6.08e-04 | 54 |
| hsa012324 | Oral cavity | OSCC | Nucleotide metabolism | 54/3704 | 85/8465 | 1.78e-04 | 5.95e-04 | 3.03e-04 | 54 |
| hsa0123211 | Oral cavity | OSCC | Nucleotide metabolism | 54/3704 | 85/8465 | 1.78e-04 | 5.95e-04 | 3.03e-04 | 54 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GMPS | SNV | Missense_Mutation | c.1766N>A | p.Arg589His | p.R589H | P49915 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-AX-A063-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| GMPS | SNV | Missense_Mutation | c.965N>T | p.Arg322Ile | p.R322I | P49915 | protein_coding | tolerated(0.07) | benign(0.007) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| GMPS | SNV | Missense_Mutation | novel | c.1391N>G | p.Asn464Ser | p.N464S | P49915 | protein_coding | tolerated(0.78) | benign(0) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| GMPS | SNV | Missense_Mutation | rs780286753 | c.112G>A | p.Gly38Arg | p.G38R | P49915 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| GMPS | SNV | Missense_Mutation | c.1367G>T | p.Cys456Phe | p.C456F | P49915 | protein_coding | tolerated(0.68) | benign(0.001) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| GMPS | SNV | Missense_Mutation | c.2030G>A | p.Arg677Gln | p.R677Q | P49915 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| GMPS | SNV | Missense_Mutation | novel | c.843N>T | p.Gln281His | p.Q281H | P49915 | protein_coding | tolerated(0.06) | possibly_damaging(0.803) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| GMPS | SNV | Missense_Mutation | novel | c.1235N>C | p.Lys412Thr | p.K412T | P49915 | protein_coding | tolerated(0.08) | possibly_damaging(0.815) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| GMPS | SNV | Missense_Mutation | novel | c.292N>G | p.Lys98Glu | p.K98E | P49915 | protein_coding | deleterious(0.04) | possibly_damaging(0.644) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GMPS | SNV | Missense_Mutation | rs190602670 | c.1650N>G | p.Ile550Met | p.I550M | P49915 | protein_coding | deleterious(0.01) | probably_damaging(0.981) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |